BOLT BIOTHERAPEUTICS INC (BOLT)
US0977021049 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to BOLT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.63. This target is 299.36% above the current price.
BOLT was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about BOLT.
In the previous month the buy percentage consensus was at a similar level.
BOLT was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-12 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-10-04 | HC Wainwright & Co. | Initiate | Buy |
| 2022-08-11 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-05-17 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-01-06 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-11-10 | SVB Leerink | Maintains | Outperform |
| 2021-08-16 | SVB Leerink | Maintains | Outperform |
| 2021-05-17 | SVB Leerink | Maintains | Outperform |
| 2021-04-06 | SVB Leerink | Maintains | Outperform |
| 2021-03-02 | Guggenheim | Initiate | Buy |
| 2021-03-02 | SVB Leerink | Initiate | Outperform |
| 2021-03-02 | Stifel | Initiate | Buy |
| 2021-03-02 | Morgan Stanley | Initiate | Overweight |